JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A
description
Transcript of JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A
![Page 1: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/1.jpg)
Angiographic V/s Functional Severity of Cor A Stenoses in the FAME Study
FFR v/s CAG in Multivessel Evaluation
JAmCollCardiol2010;55:2816–21Tonino, Fearon et al.
Frijo Jose A
![Page 2: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/2.jpg)
Objectives
• To investigate the relationship between angiographic and functional severity of cor A stenoses in the FAME study
![Page 3: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/3.jpg)
Background
• CAG may result in both underestimation & overestimation of a lesion’s severity & is often inaccurate in predicting which lesions cause ischemia
![Page 4: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/4.jpg)
Principle
• FFR valueof <0.80 identifies ischemia-causing coronary stenoses with an accuracy of >90%
![Page 5: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/5.jpg)
Fractional flow reserve
– During maximum vasodilation– Mean cor pressure/mean Ao pressure– Unaffected by alteration in resting flow– Can immediately assess importance of a lesion for
guiding intervention– Considerable prognostic information– FFR more than 0.8- excellent outcome with deferred
rather than prophylactic intervention– Most direct way to assess physiological significance of
a lesion
![Page 6: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/6.jpg)
Clinical uses of FFR
1. Determining the hemodynamic significance of CAG intermediate lesions:
• Pijls et al - cutoff 0.75 detected ischemia – sensitivity- 88%, specificity- 100%, diagnostic accuracy- 93%
• DEFER - moderate CAD + FFR>0.75 - PCI v/s medical – PCI event rate > medical event rate
![Page 7: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/7.jpg)
Clinical uses of FFR
2. Determining success of PCI: • Multicenter registry - FFR determined
immediately after stenting – most signi independent variable related to future events
![Page 8: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/8.jpg)
Clinical uses of FFR
3. Determining significance of LMCA lesions: • Bech et al- 54pts (29/12)- equivocal LMCA• Medical - 24 pts with FFRs >0.75• CABG - 30 pts with FFR <0.75 • Survival – medical- 100%, CABG- 97%
![Page 9: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/9.jpg)
Clinical uses of FFR
4. Determining the significance of multiple stenoses in the same coronary artery:
• FFR can be used to “map” the hemodynamic effects of multiple stenoses in the same vessel
• FAME
![Page 10: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/10.jpg)
Recommendations for Use of Fractional Flow Reserve
Class IIa• Can be useful to determine whether PCI of a specific
cor lesion is warranted• Can be useful as an alternative to performing
noninvasive functional testing (eg, when the functional study is absent or ambiguous) to determine whether an intervention is warranted
• In the assessment of the effects of intermediate cor stenoses (30% to 70% luminal narrowing) in pts with anginal symptoms
![Page 11: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/11.jpg)
Inclusion
• Mul-tivessel CAD, defined as cor A stenoses of ≥50% of vessel diameter in ≥2 of 3 major epicardial cor A, & if PCI was indicated
![Page 12: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/12.jpg)
Exclusion
• Left main coronary disease• Previous CABG• Recent STEMI(<5days)• Recent N-STEMI(<5days) if peak CK is >1000IU• Cardiogenic shock• Extremely tortuous/calcified cor• Lifeexpectancy <2y• Pregnancy• Contraindication for DES placement
![Page 13: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/13.jpg)
![Page 14: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/14.jpg)
![Page 15: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/15.jpg)
• In this subanalysis of the FAME study, the relationship between CAG & FFR in all pts in the FFR-guided arm ( 509) was analyzed
• 1,005 pts with multi vessel disease were randomly assigned to CAG –guided PCI ( 496) or FFR-guided PCI ( 509)
![Page 16: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/16.jpg)
• Categorized the lesions according to visual CAG stenosis severity into 50%to70%, 71%to90%, & 91%to100% diameter stenosis
• In those randomized to FFR guidance, if the FFR of a particular stenosis was >0.80, -was considered as functionally nonsignificant & no stent was placed
• The definition of functional 0-,1-,2-,or3-VD was made on basis of no of main arteries with an FFR <0.80
• So, a pt with CAG 3- VD could be classified as having functional 0-,1-,2-,or3-VD, after FFR
![Page 17: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/17.jpg)
Serial stenoses• Stenting is only performed if FFR beyond all narrowings
is≤0.80• Investigator then stents the narrowing that appears most
signi or is responsible for largest P gradient during pullback of P sensor
• After stenting 1st lesion, FFR is measured again & any residual narrowing causing an FFR ≤0.80 is stented
• IV adenosine as opposed to intra-coronary adenosine because IV adenosine provides prolonged hyperemia, which allows adequate time to perform a pullback of the pressure wire and localize pressure gradients
![Page 18: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/18.jpg)
• In all FFR-guided pts, investigator is encouraged to measure a final FFR aft PCI
• Although the final FFR measurement can be quite useful for assessing PCI result, it is not mandated in protocol in an attempt to keep the procedure as simple as possible
![Page 19: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/19.jpg)
primary end point (1yr)
• Rate of death• Nonfatal myocardial infarction • Repeat revascularization
![Page 20: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/20.jpg)
• In pts presenting with a NSTEMI & ↑CK-MB before PCI, if peak CK-MB has not occurred, a periprocedural MI will be defined as – Recurrent chest pain lasting for ≥30 m OR new ECG
changes consistent with a 2nd MI – & an ↑ in CK-MB by ≥50% of the preprocedure CK-
MB level• If the pre-PCI CK-MB is falling or already N, then
a periprocedural MI will be defined as a CK-MB ↑ ≥3 times upperlimit of N & a 50% ↑from pre-PCI CK-MB level
![Page 21: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/21.jpg)
Results
• FFR-guided arm of the FAME study -509 pts• 1,414 lesions –indicated before randomization
–FFR was measured successfully in 1,329(94%) of the 1,414 lesions
• 620(47%) - 50%to70%category• 513(39%) - 71%to90%category• 196(15%) - 91%to99%category
![Page 22: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/22.jpg)
• Of all 1,329 lesions, 816(61%) were below ischemic threshold (FFR ≤0.80)
• Of 50%to70% category, in 402(65%), FFR was >0.80 and in 218(35%), FFR was ≤0.80
• Of 71%to90% category, in104(20%), FFR was >0.80 and in 409(80%), FFR was ≤0.80
• In 91%to99% category,7(4%) FFR >0.80 and 189(96%) had FFR ≤0.80
![Page 23: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/23.jpg)
![Page 24: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/24.jpg)
![Page 25: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/25.jpg)
Discussion
• All stenoses with CAG severity 50%to70%, 65% - functionally nonsigni & 35% - functionally signi by FFR
• In more severe stenoses 71%-90% CAG severity- 20% did not induce reversible myo ischemia as established by FFR
![Page 26: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/26.jpg)
![Page 27: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/27.jpg)
• In pts with multivessel CAD, routine measurement of FFR during PCI, as compared with the standard strategy of PCI guided by CAG, signi ↓ rate of 1˚composite end point of death, MI, & repeat revasc at 1 year
• The combined of death & MI was also signi ↓• Without prolonging the procedure, the FFR-
guided strategy ↓the no of stents used, ↓ the amount of contrast agent used
![Page 28: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/28.jpg)
![Page 29: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/29.jpg)
![Page 30: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/30.jpg)
Diabetic Atherosclerosis Preventionby Cilostazol (DAPC) Study
Katakami, Young-SeolKim et al.Circulation.2010;121:2584-2591
![Page 31: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/31.jpg)
Background
• Anti-platelet drugs are effective in preventing recurrence of atherosclerosis in T2 DM.
• However, the efficacy & usefulness of 2 different antiplatelet drugs, aspirin and cilostazol, in the progression of carotid intima-media thickening are unknown.
![Page 32: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/32.jpg)
Aim
• To compare cilostazol and aspirin in prevention of progression of atherosclerosis
![Page 33: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/33.jpg)
• T2-DM aged 40-85years at the time of enrollment who were suspected of having PAD on the basis of an ABI of <1.0, poor pulsation bilaterally or substantially weaker pulsation on either side in the case of the popliteal artery or dorsalis pedis artery, and/or clinical symptoms of PAD
![Page 34: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/34.jpg)
• 329 type2 DM suspected of PAD were allocated to either
• Aspirin-treated(81to100mg/d)group - 152• Cilostazol-treated(100to200mg/d)gp-145
• The changes in intima-media thickness of the common carotid artery during a 2-year observation period were examined as the primary endpoint
![Page 35: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/35.jpg)
Results
• In pts in cilostazol gp, there was signi improvement in max & mean left CCA-IMT during treatment compared with baseline; max & mean right CCA-IMT also exhibited a tendency toward improvement
• In pts in the aspirin gp- there was signi ↑in max left, max right, and mean right CCA-IMT from baseline
![Page 36: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/36.jpg)
Conclusions
• Compared with ASA, cilostazol potently inhibited progression of carotid IMT, an established surrogate marker of CV events, in pts with type2 DM
![Page 37: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/37.jpg)
![Page 38: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/38.jpg)
Effects of Intensive BP Control in T-2 DM
ACCORD-BP
Cushman, Evans et al.N Engl J Med 2010;362:1575-85.
![Page 39: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/39.jpg)
Background
• There is no evidence from randomized trials to support a strategy of lowering SBP <135 to 140 mm Hg in persons with T2DM
![Page 40: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/40.jpg)
Aim
• Whether therapy targeting normal SBP (i.e., <120 mm Hg) ↓ major cardiovascular events in participants with type 2 diabetes at high risk for cardiovascular events
![Page 41: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/41.jpg)
• 4733 type 2 DM• Intensive therapy- SBP-< 120 mm Hg• Standard therapy- SBP-< 140 mm Hg
![Page 42: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/42.jpg)
• The ACCORD BP trial was a study of a treatment strategy to achieve specific SBP goals, rather than an evaluation of any specific drug regimen
![Page 43: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/43.jpg)
• Type 2 diabetes mellitus and a glycated hemoglobin level of 7.5% or more
• And were ≥40 yrs with CV disease or ≥55 yrs with anatomical evidence of a substantial amount of atherosclerosis, albuminuria, LVH, or at least two additional risk factors for CVD (DLP, HTN, smoking, or obesity)
![Page 44: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/44.jpg)
Primary composite outcome• nonfatal MI, nonfatal stroke, or death from CV
causesThe mean follow-up - 4.7 years
![Page 45: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/45.jpg)
Results
• Mean SBP- 119.3 mm Hg intensive & 133.5 mm Hg standard
• Annual rate of primary outcome - 1.87% (intensive) & 2.09% (standard), P = 0.20)
• Annual rates of death from any cause -1.28% and 1.19% ; P = 0.55
• Annual rates of stroke- 0.32% and 0.53% ; P = 0.01• Serious adverse events attributed to anti-HTN
treatment -77 of 2362 (intensive-3.3%) and 30 of 2371 (standard-1.3%)- P<0.001
![Page 46: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/46.jpg)
![Page 47: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/47.jpg)
![Page 48: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/48.jpg)
![Page 49: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/49.jpg)
![Page 50: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/50.jpg)
![Page 51: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/51.jpg)
![Page 52: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/52.jpg)
Conclusions
• In pts with T2 DM at high risk for CV events, targeting a SBP of <120 mm Hg, as compared with <140 mm Hg, did not reduce rate of a composite outcome of fatal & nonfatal major cardio-vascular events.
![Page 53: JAmCollCardiol2010;55:2816–21 Tonino , Fearon et al. Frijo Jose A](https://reader035.fdocument.pub/reader035/viewer/2022081420/56815d1e550346895dcb1b2f/html5/thumbnails/53.jpg)
THANKS..